Albumin levels as a biomarker for second Intravenous Immunoglobulin (IVIG) treatment in Guillain-Barre syndrome (GBS)

Anna Shalman, Shiri Savir, Yana Mechnik Steen, Andrey Ovanyan, Nancy Boniel, Leonid Koyfman, Yoav Bichovsky, Alexander Zlotnik, Moti Klein, Evgeni Brotfain

    Research output: Contribution to journalArticlepeer-review

    6 Scopus citations

    Abstract

    Background: Patients with GBS may develop hypoalbuminemia following treatment with Intravenous Immunoglobulin (IVIG), which is related to a poorer outcome. This report presents a patient with GBS and his clinical response to two courses of IVIG treatments in association with his albumin level. Case report: A previously healthy 21-year-old male was admitted to the GICU due to GBS with severity grade 5 (required assisted ventilation). IVIG treatment was initiated. Over the next two weeks there was no clinical improvement and Albumin level dropped from 4.5 gr/dL to a nadir of 2.3 gr/dL. A second course of IVIG was initiated. After initiation of the second course the patient's albumin began rising to 3.0 gr/dL and a clinical improvement followed this rise. Subsequently, he was weaned from mechanical ventilation within a few days. Conclusions: When considering a second course of IVIG treatment, serum albumin levels may be considered a biomarker as part of the decision algorithm.

    Original languageEnglish
    Pages (from-to)247-249
    Number of pages3
    JournalJournal of Clinical Neuroscience
    Volume74
    DOIs
    StatePublished - 1 Apr 2020

    Keywords

    • Guillain-Barre Syndrome
    • Hypoalbuminemia
    • Intravenous Immunoglobulin
    • Serum albumin

    ASJC Scopus subject areas

    • Surgery
    • Neurology
    • Clinical Neurology
    • Physiology (medical)

    Fingerprint

    Dive into the research topics of 'Albumin levels as a biomarker for second Intravenous Immunoglobulin (IVIG) treatment in Guillain-Barre syndrome (GBS)'. Together they form a unique fingerprint.

    Cite this